Ongoing preclinical trials and translational research into the PD-1/PD-L1 axis in lymphoma will assess the effectiveness of PD-1/PD-L1 inhibitors in PD-1/PD-L1-positive r/r B cell and T cell lymphoma. This evidence concerns the gene CD274 and T-cell non-Hodgkin lymphoma.